Rezolute Stock Today
| RZLT Stock | USD 4.86 0.05 1.02% |
Performance2 of 100
| Odds Of DistressLess than 21
|
Rezolute is selling for under 4.86 as of the 25th of November 2024; that is 1.02 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 4.85. Rezolute has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Rezolute are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of May 2014 | Category Healthcare | Classification Health Care |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. The company has 57.94 M outstanding shares of which 1.12 M shares are at this time shorted by private and institutional investors with about 3.16 trading days to cover. More on Rezolute
Moving against Rezolute Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rezolute Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, Founder | Nevan JD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRezolute can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rezolute's financial leverage. It provides some insight into what part of Rezolute's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Rezolute (RZLT) is traded on NASDAQ Exchange in USA. It is located in 275 Shoreline Drive, Redwood City, CA, United States, 94065 and employs 59 people. Rezolute is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 284.5 M. Rezolute conducts business under Biotechnology sector and is part of Health Care industry. The entity has 57.94 M outstanding shares of which 1.12 M shares are at this time shorted by private and institutional investors with about 3.16 trading days to cover.
Rezolute currently holds about 150.41 M in cash with (57.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.87.
Check Rezolute Probability Of Bankruptcy
Ownership AllocationRezolute owns a total of 57.94 Million outstanding shares. Over half of Rezolute's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Rezolute Ownership Details
Rezolute Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1 M | |
| Ikarian Capital, Llc | 2024-09-30 | 887.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 800.5 K | |
| Velan Capital Investment Management Lp | 2024-06-30 | 800 K | |
| Geode Capital Management, Llc | 2024-09-30 | 491.6 K | |
| Opaleye Management Inc | 2024-09-30 | 466.6 K | |
| Ubs O'connor Llc | 2024-09-30 | 439.2 K | |
| Citadel Advisors Llc | 2024-09-30 | 376.3 K | |
| Blackrock Inc | 2024-06-30 | 365.9 K | |
| Federated Hermes Inc | 2024-09-30 | 11.3 M | |
| Vivo Capital, Llc | 2024-09-30 | 2.8 M |
Rezolute Historical Income Statement
Rezolute Stock Against Markets
Rezolute Corporate Management
| Raj MD | VP Development | Profile | |
| Michael Deperro | Senior Development | Profile | |
| LLM JD | Chief Officer | Profile | |
| Gopal MBBS | Senior Development | Profile | |
| MD MBA | Director Affairs | Profile | |
| Daron Evans | Chief Officer | Profile | |
| Erin OBoyle | Senior Operations | Profile |
Additional Tools for Rezolute Stock Analysis
When running Rezolute's price analysis, check to measure Rezolute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rezolute is operating at the current time. Most of Rezolute's value examination focuses on studying past and present price action to predict the probability of Rezolute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rezolute's price. Additionally, you may evaluate how the addition of Rezolute to your portfolios can decrease your overall portfolio volatility.